KOD

Kodiak SciencesC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

Positive GLOW2 topline leads to an expedited regulatory path and clear submission timeline; strong uptake expectations in the addressable diabetic retinopathy market and favorable pricing/coverage assumptions drive material upside to the anchor.

Posture

Mixed

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta +24.1.

What can break

Commercial uptake and reimbursement uncertainty

Momentum

Value

Sentiment

Setup hits (3d)

— · Net —

AI TargetsBase $42.00 · Bull $70.00 · Bear $18.00

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-03-27 • Model: RankAlpha Sentiment AI

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade C · Mixed

Confidence Medium · Net —

Target $62.67

Why

Momentum87 · Δ7d +24.1

Value41 · Δ7d -0.1

Sentiment41 · Δ7d -6.1

So what

Balanced signals. Wait for confirmation before sizing up.

Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits

Lead driver: Momentum · See technicals

Momentum

26% active weight

Current posture

7d trendFlat

Δ7d

+24.1

Δ21d

+39.4

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.1

Δ21d

0.0

Sentiment

34% active weight

Current posture

7d trendSoftening

Δ7d

-6.1

Δ21d

-18.9

Why this grade

Composite grade C. Momentum 86.8 / Value 41.1 / Sentiment 40.9

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$2.67B

Beta

2.65

Shares Out

62.58M

P/E (TTM) · Derived

-9.9

P/S (TTM)

P/FCF (TTM) · Derived

-15.98

Rev YoY

EPS YoY

-13.7%

Gross Margin

Op Margin

Net Debt

-$50.68M

Current Ratio

3.54

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology